Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut check: bacteria linked to blood pressure in new study

NCT ID NCT06284928

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the gut bacteria of 192 people, including those with untreated high blood pressure, treated high blood pressure, and healthy individuals. Researchers analyzed stool samples to find differences in bacteria types and functions. The goal was to understand how gut microbes relate to blood pressure and identify possible targets for better treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

192 people

The number who actually took part.

Started

Dec 2019

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults aged 18 years or older recruited from the outpatient clinics and health examination centers of the First Affiliated Hospital of Xinjiang Medical University. Participants include three groups: newly diagnosed untreated hypertensive patients, hypertensive patients receiving medication but with uncontrolled blood pressure, and healthy controls without hypertension or major chronic diseases. All participants will provide stool samples for gut microbiota metagenomic analysis and basic clinical data collection.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria General Inclusion (applies to all participants) 1. Adults aged 18 years or older. 2. Able and willing to provide a stool sample for gut microbiota analysis. 3. Able to understand and sign written informed consent prior to participation. Cohort-Specific Inclusion A. Untreated Hypertension Group (Newly Diagnosed) 1. Newly diagnosed hypertension, defined as: Office blood pressure ≥140/90 mmHg, confirmed by at least two measurements on separate visits; or 24-hour ambulatory BP monitoring (ABPM): mean ≥130/80 mmHg, or daytime ≥135/85 mmHg, or nighttime ≥120/70 mmHg. 2. Never received any antihypertensive medication prior to enrollment. B. Uncontrolled Hypertension Group (On Medication) 1. Established hypertension, under stable antihypertensive therapy for ≥4 weeks. 2. Blood pressure not at target, defined as: Office BP ≥140/90 mmHg, or 24-hour ABPM mean ≥130/80 mmHg (daytime ≥135/85 mmHg, nighttime ≥120/70 mmHg). 3. No planned medication changes until stool sampling is completed. C. Healthy Control Groups 1. No history of hypertension or antihypertensive medication use. 2. Office BP \<130/80 mmHg (average of 2-3 readings). 3. Free from major chronic or gastrointestinal diseases. Exclusion Criteria 1. Use of antibiotics, probiotics, or prebiotics within the previous 3 months, or bowel preparation for colonoscopy within 4 weeks. 2. Chronic gastrointestinal diseases (e.g., inflammatory bowel disease, irritable bowel syndrome, celiac disease) or history of major gastrointestinal surgery (including bariatric surgery). 3. Presence of major chronic diseases that may confound gut microbiota or blood pressure regulation, including: Coronary artery disease (CAD) or other significant cardiovascular diseases; Diabetes mellitus (type 1 or type 2); Chronic kidney disease (stage ≥3); Chronic liver disease or hepatic failure; Heart failure (NYHA class III-IV); Active malignancy or history of cancer within the past 5 years. 4. Pregnancy or lactation. 5. Acute infection, acute gastrointestinal symptoms, or hospitalization within the past 4 weeks. 6. Special restrictive diets (e.g., ketogenic, elimination, or medically prescribed weight-loss diets) or alcohol/substance abuse that may alter gut microbiota. 7. Any other condition that, in the investigator's opinion, could interfere with participation, data integrity, or sample quality.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gut microbiota are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, 630000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.